Development and evaluation of an automated quantification tool for amyloid PET images
Tóm tắt
Quantitative evaluation of amyloid positron emission tomography (PET) with standardized uptake value ratio (SUVR) plays a key role in clinical studies of Alzheimer’s disease (AD). We have proposed a PET-only (MR-free) amyloid quantification method, although some commercial software packages are required. The aim of this study was to develop an automated quantification tool for amyloid PET without using commercial software.
The quantification tool was created by combining four components: (1) anatomical standardization to positive and negative templates using NEUROSTAT
Compared with manual step-by-step processing, our developed automated quantification tool reduced processing time by 85%. The SUVRs obtained by the developed quantification tool were consistent with those obtained by manual processing. Compared with the conventional PMOD-based method, the developed quantification tool provided 1.5% lower SUVR values, on average. We determined that this bias is likely due to the difference in anatomical standardization methods.
We developed an automated quantification tool for amyloid PET images. Using this tool, SUVR values can be quickly measured without individual MRI and without commercial software. This quantification tool may be useful for clinical studies of AD.
Từ khóa
Tài liệu tham khảo
Japanese Ministry of Health, Labor and Welfare. Comprehensive Strategy for Promotion of Policy Measures against Dementia. (New Orange Plan). 2017. https://www.mhlw.go.jp/file/06-Seisakujouhou-12300000-Roukenkyoku/kaitei_orangeplan.pdf. (in Japanese). Accessed 8 June 2020.
Asada T. Prevalence of Dementia in Japan: Past, Present and Future. Rinsho Shinkeigaku. 2012;52(11):962–4.
Viola KL, Klein WL. Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129(2):183–206.
Cho H, Choi JY, Hwang MS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247–58.
Sasaki M, Kuwahara Y. Nuclear Medicine Technology. Tokyo: Nanzando Co.Ltd; 2016. p. 229–30.
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–19.
Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46(12):1959–72.
Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363–72.
Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016;537(7618):50–6.
Choi WH, Um YH, Jung WS, et al. Automated quantification of amyloid positron emission tomography: a comparison of PMOD and MIMneuro. Ann Nucl Med. 2016;30(10):682–9.
Tuszynski T, Rullmann M, Luthardt J, et al. Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2016;43(6):1077–87.
Parani D, Iaccarino L, Bettinardi V. The need for “objective measurements” in FDG and amyloid PET neuroimaging. Clin Transl Imaging. 2014;2:331–42.
Akamatsu G, Ikari Y, Ohnishi A, et al. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI. Phys Med Biol. 2016;61(15):5768–80.
Ikari Y, Nishio T, Makishi Y, et al. Head motion evaluation and correction for PET scans with 18F-FDG in the Japanese Alzheimer’s disease neuroimaging initiative (J-ADNI) multi-center study. Ann Nucl Med. 2012;26(7):535–44.
Minoshima S, Koeppe RA, Frey KA, et al. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med. 1994;35(9):1528–37.
PMOD Technologies, Llc. PMOD Image Fusion (PFUS) User’s guide. 2015.
Bourgeat P, Villemagne VL, Dore V, et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging. 2015;36(Suppl 1):S159–66.
Leuzy A, Chiotis K, Lemoine L, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24(8):1112–34.
Chen MK, Mecca AP, Naganawa M, et al. Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol. 2018;75(10):1215–24.
Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp. 1999;7(4):254–66.
Hosaka K, Ishii K, Sakamoto S, et al. Validation of anatomical standardization of FDG PET images of normal brain: comparison of SPM and NEUROSTAT. Eur J Nucl Med Mol Imaging. 2005;32(1):92–7.
Ishii K, Willoch F, Minoshima S, et al. Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med. 2001;42(4):548–57.